Table S7 from Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer

Cristina Santos,Daniel Azuara,Rocio Garcia-Carbonero,Pilar Garcia Alfonso, Alfredo Carrato,Mª Elena Elez,Auxiliadora Gomez,Ferran Losa, Clara Montagut,Bartomeu Massuti,Valenti Navarro,Mar Varela,Adriana Lopez-Doriga,Victor Moreno,Manuel Valladares,Jose Luis Manzano,Jose Maria Vieitez,Enrique Aranda,Xavier Sanjuan,Josep Tabernero, Gabriel Capella,Ramon Salazar

crossref（2023）

引用 0|浏览0

暂无评分

摘要

S7. Progression-free survival and overall survival in the cohort of patients treated with anti-EGFR in first-line (N= 83) and in second line and beyond (N = 99).

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要